pharma · GLAND
Gland Pharma
Gland Pharma: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Price
₹2,517
Price 2026-07-30
5 day
+5.77%
Short-term move
1 month
+0.88%
Medium-term
Regime
NARROW LEADERSHIP
62% confidence
Market cap
₹42.1k Cr
inflow sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's NARROW LEADERSHIP regime affect Gland Pharma (GLAND) in the pharma sector?”
Price chart
₹2,428
+33.67% over period
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -10.0% over 14 days) — not a reliable pattern.
52-week position
Trading at 98.2% of 52-week high
Technicals
RSI 14
53.5
Trend
uptrend
50 DMA
Above
200 DMA
Above
Key metrics
P/E ratio
40.9
86th pct · 7 quarterly points (limited history)
P/B
4.1
ROE
10.5%
Moderate profitability — 10.5% ROE
Market cap
₹42.1k Cr
Revenue growth
2230.0% YoY
Promoter
51.8%
52-week range
₹1,573.6 – ₹2,562.9
98.2% of high
RSI (14)
53.5
uptrend
vs 50 DMA
Above
DMA ₹2,359.34
Coverage
100/100
HIGH
Quick Take
Gland Pharma: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹7,835 | +7.7% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,466.4 | +5.3% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,144.8 | -1.8% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,576.3 | +3.5% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| ALKEM Alkem Laboratories | ₹5,816.5 | +3.8% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| BIOCON Biocon | ₹425.35 | -2.3% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,190.3 | -0.7% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| JBCHEPHARM J B Chemicals | ₹2,408.9 | +0.0% | 54.5 | 18.7% | -480% | ₹38.9k Cr |
| GLAND Gland Pharma | ₹2,517 | +5.9% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
Tensions to watch
Promoter holding at 51.8% — neither distress selling nor aggressive buying
No strong insider signal. Watch for changes in promoter stake as a leading indicator.
Key Watchpoints
Breaks above ₹2643 (+5%)
Trend reversal confirmation
Breaks below ₹2391 (-5%)
Further downside risk
PE reverts to median of 34.8 (7 quarterly points (limited history))
Valuation normalization
Pharma sector holding leadership position
Sector momentum continuing
